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Abstract 
Brain Natriuretic Peptide is an amino acid polipeptide produced by cardiac myocytes, whose 
synthesis results mainly from hemodynamic changes that lead to atrial or ventricular volume 
expansion. The peptide is released primarily by the ventricular myocardium and its 
fragmentation and cleavage lead to the formation of NTproBNP. 
Several studies have been discovering different applications of these biomarkers, with special 
focus on diagnosis, prognosis and monitoring of therapy of congestive heart failure. However, 
in the past few years several other disease states have been associated with changes on the 
systemic levels of these proteins. 
Therefore, we aimed to review the possible applications of NTproBNP and BNP beyond 
Congestive Heart Failure, with specific emphasis in the following diseases: Ischemic Stroke, 
Atrial Fibrillation, Carotid Artery Stenosis, Aortic Valve Stenosis, Coronary Heart Disease, 
Hypertrophic Cardiomyopathy, Tachycardia-mediated Cardiomyopathy, Takotsubo 
Cardiomyopathy, Heart Surgery, Kawasaki Disease, Central Sleep Apnea, Sepsis, Chronic 
Kidney Disease and Pleural Effusions.  
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Introduction
The use of biomarkers as a noninvasive tool, has become common in several areas of 
medicine, due to its usefulness in the diagnosis and prognosis of countless diseases [1].  
Brain natriuretic peptide (BNP) and amino terminal pro-brain natriuretic peptide 
(NTproBNP) are neurohormones secreted by cardiomyocites in response to volume expansion 
and increased pressure [2]. Therefore, they have a high potential for application in several 
fields of medicine.  
They are used primarily in emergency situations, namely in the differential diagnosis of 
dyspnea, which may in some circumstances be difficult only by clinical signs. When this is 
the case, support of a cardiac etiology can be obtained by the use of biomarkers, improving 
assessment and speeding up treatment [3]. 
Despite various applications, it’s important to consider that, there are some factors that 
may affect the plasma concentrations of these neuropeptides, and therefore measured levels 
should be adapted to each situation. Likewise, its pathophysiological mechanisms are not yet 
fully clarified [4].  
The aim of this study was to determine the usefulness of BNP/NTproBNP as a biological 
marker, for the prediction, diagnosis, monitoring and treatment of situations other than acute 
and chronic heart failure and eventual role in providing risk stratification. Thus, we intend to 
document the possible role of these biomarkers as an important additional diagnostic tool, 
leading to a better outcome in a new spectrum of diseases [1]. However, understanding their 
contribution implies knowing the pathophysiology behind these disease states, something that 
also be briefly covered. 
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Methods 
A search to evaluate the clinical application of BNP or NTproBNP, was performed in 
PubMed, using the following keywords: “BNP”, “NTproBNP” and “clinical applications”, 
from October 2012 to December 2012. 
The search provided 561 results, among which 4 described biology and function of 
these biomarkers and 41 were related with other diseases besides heart failure. An additional 
11 articles were retrieved from the reference list of the aforementioned articles and 19 articles 
from manual searches related with specific subjects associated with BNP/NTproBNP. 
A total of 75 articles were used in this review article comprising mostly papers 
published between 2005 and 2012 (figure 1). 
 
. 
 
 
 
 
 
 
 
Figure 1. Flowchart illustrating the article(s) selection process. 
 
1. BNP/NTproBNP: Biology  
Brain natriuretic peptide (BNP) is a neurohormone secreted by cardiomyocites in 
response to hemodynamic stress. The BNP gene, located in chromosome 1, encodes 134 
amino acid preprohormone (BNP) that is cleaved into a 108 amino acid, proBNP. This 
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hormone is then cleaved again, by a proteolytic enzyme, into the biologically active 
prohormone called NTproBNP [3]. Both of these hormones (BNP and NTproBNP) are 
produced at equimolar levels by ventricular myocites, but NTproBNP has a longer half-life 
(3), rendering it useful for improving the diagnostic threshold of some diseases [5].   
These biomarker levels reflect the hemodynamic status [4], because they are secreted as a 
response to ventricular volume expansion and electrolytic imbalance, which causes increased 
intraventricular pressure or stretch and resultant increased wall tension [2,3]. However, when 
a patient has atrial dysfunction, such as in atrial fibrillation (AF), the main source of brain 
natriuretic peptide is the atrium [6]. The hormones are released in these circumstances as a 
way of attenuating these hemodynamic changes, since they have a natriuretic, diuretic and 
vasodilator effect. They decrease the preload and afterload and consequently decrease 
pressure, smooth muscle and fibroblast proliferation (preventing fibrosis), and reduce the 
antidiuretic hormone and aldosterone synthesis to reduce salt and water retention [4].  
Despite their hemodynamic effects, the concentration of the hormones may vary between 
patients, which can be explained by a few factors. One of the most frequent, positively 
correlated with BNP levels is age, which increases alongside with myocardial mass. 
Conversely, aging leads to the reduction of the renal clearance [4, 7]. Gender is also a part of 
the equation: women have higher BNP levels than men, probably because of the influence of 
sex hormones on gene expression [4, 7]. Even obesity has an important part, and has been 
shown to have an inverse correlation with peptide levels [4]. 
Despite these different interactions and limitations, BNP/NTproBNP can be seen as 
quantitative markers, useful in triage of patients.   
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2. Clinical applications 
In general, in most cardiac diseases that have been associated with an increase in the B-
type natriuretic peptides [7] focus has been placed in the presence of left ventricular 
dysfunction [4]. However, several studies have shown that several other conditions may be 
associated with an increase in BNP/NTproBNP.  
 
2.1.   Ischemic Stroke: 
Nowadays, the diagnosis of stroke is based on neuroimaging assessment and clinical 
symptoms. However, other methods may be important to early differentiate between 
hemorrhagic and ischemic stroke, or exclude other pathologies, allowing to promptly initiate 
therapy [1]. 
Shibazaki K and co-workers assessed 227 patients with atrial fibrillation within 24 hours 
of onset of transient ischemic attack (TIA) or stroke. Plasma BNP levels were measured on 
admission and were lower in TIA than in stroke. These authors suggested an optimal cutoff 
level of 120pg/ml, with values above this threshold being associated with stroke and 
neurological severity. They also proposed that plasma BNP levels can be used to predict 
embolic source independently, with a cutoff point of 140 pg/ml [8]. 
Montaner and co-workers, confirmed that BNP levels were higher in patients suffering 
from acute cardioembolic stroke (CE) than in other etiologies. They suggested a cutoff level 
of BNP>76 pg/mL associated with D-dimer >0,96 mg/mL to predict this event [9].  
Santamarina and colleagues, evaluating 294 patients with ischemic stroke, of which 89 
had an unknown origin, BNP >64pg/mL and CK-MB >1,5 mg/ml were independent 
predictors of embolic source [10].  
However, Tamura et al measured plasma BNP levels in 223 patients in 7 days after 
ischemic stroke, without history of heart failure and found a cutoff point of 90pg/ml, over 
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which cardiogenic stroke was more likely than cryptogenic stroke [6]. In other stroke types, 
there was a release of BNP, albeit less pronounced.  
Concerning NT-proBNP, Fonseca et al, conducted a study that showed a positive 
association between this peptide and cardioembolic stroke. They estimated a best cut-off point 
of NT-proBNP discriminating an embolic source was > 265.5 pg/ml. When restricted to 
patients with AF, sensitivity increased from 71.4 to 94.4% while maintaining a similar 
specificity. (73.7 to 72.9%, respectively) [11].  
Despite the possibility of using BNP plasma levels to elucidate stroke etiology, this 
neuropeptide can also be used to predict the prevalence of cardiac abnormalities like 
arrhythmia, coronary or valvular diseases. These diseases states affect ventricular and atrial 
cardiomyocites leading to the release of the neuropeptides [12].  
Chen and co-workers have shown that NTproBNP plasma level alongside with the 
NIHSS scale (National Institutes of Health Stroke Scale) allowed a combined risk 
stratification and prognostication of patients. NIHSS is a 15-item neurologic examination 
stroke scale used to objectively quantify the initial stroke severity/neurologic deficit and 
predict mortality. They also suggested cut-off points of 1,583.50 pg/ml for NTproBNP, and 
NIHSS score on admission > 12.5 to detect the group of patients with a higher mortality rate 
[13].  
Among patients with cerebral infarction, the association is more pronounced in those 
without angiographic vasospasm, suggesting that BNP adequately detects patients with 
ischemic stroke where large vessel vasospasm was not the main mechanism [14].  
Plasma BNP levels seem to have promising applications in stroke (figure 2), and it would 
be wise to confirm and externally validate optimal cut-off points, allowing the differentiation 
of the different associated conditions and optimization of treatment.  
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Figure 2: Proposal of a diagnostic approach (and likelihood of cardiac diseases) to the patient 
with cerebral ischemic event according to BNP/NTproBNP levels. Cutoff values are 
presented as examples based on presented investigations, but are yet lacking external 
validation. AF – atrial fibrillation; BNP – brain natriuretic peptide; TIA- transient ischemic 
attack. 
 
2.2. Atrial Fibrillation (AF): 
I. Predictor of changes in patients with AF: 
A study conducted by, Tamura et al, described a strong association between increased 
BNP levels, independently of AF or sinus rhythm, and the presence of left atrial appendage 
(LAA) dysfunction [6]. Another retrospective study supported this association, with an 
increase in the BNP levels being related to a decreased LAA flow velocity (i.e. LAA 
dysfunction) [15].  
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Furthermore, in a group of AF patients with and previous stroke, BNP levels have been 
identified as a marker of left atrial thrombus: levels higher than 140pg/ml were a predictor of 
atrial thrombus, but with low sensitivity and specificity (76,5% and 62%, respectively) [16].  
According to Shibazaki and colleagues, in 584 patients with previous stroke and without 
previously known AF, 40 patients were diagnosed with AF during follow-up. It was observed 
that the incidence of the arrhythmia increased alongside with BNP levels: 2% in patients with 
<50pg/ml, 4% in  50 to 100pg/ml, 12% in 100 to 200 pg/ml, 26% in 200 to 400 and 38% with 
above 400 pg/ml. They also established a cutoff point of  > 65pg/ml that categorized patients 
according to their risk to develop AF [17].  
 
II. Predictor of stroke and mortality in patients with AF: 
The strongest evidence in favor of the association of these peptides with stroke and 
thromboembolism in AF derives from the RE-LY trial biomarker sub-analysis. In this post-
hoc analysis, in 6,189 patients with AF under anticoagulant therapy, troponin I and 
NTproBNP levels were assessed at baseline. These were found to positively correlate with the 
risk of stroke and short and long-term mortality [18]. Usually the CHADS2 score is used for 
risk stratification in patients with AF, and in this study it was possible to observe the additive 
value of troponin I and NTproBNP to this scale. e.g., In patients with low risk (classification 
of 0 to 1), an increase in biomarkers (troponin I ≥ 0,020 ug / l and NTproBNP <387 ng/L ) 
doubled the risk of thromboembolism and high levels (troponin I≥ 0,040 ug / l and and 
NTproBNP >1402 ng/L) increased the risk approximately five times [18]. 
This confirms the preliminary results by Kurl and co-workers suggesting that NTproBNP 
might help identifying subjects at risk for stroke and AF [19].  
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In a small cohort study, a similar association was found for BNP. It predicted 
thromboembolic events in AF patients under anticoagulant therapy, and an optimal cut-off 
value of 218 pg / ml was established [20]. 
 
III. Predictor of atrial fibrillation incidence, type and duration: 
Several studies have related the presence of AF with NTproBNP levels. It was suggested 
that, in patients without structural cardiac disease, those with AF, showed increased 
NTproBNP levels [21]. This was confirmed in the Cardiovascular Health Study [22] and in 
Prevention of Renal and Vascular Endstage Disease (PREVEND) [23] cohorts, where this 
biomarker was a predictor of the incidence of AF.  
In 5,187 individuals from the Malmö Diet and Cancer Study (MDCS) NTproBNP 
modestly improved the discrimination of AF during a mean follow-up of 14 years when added 
to conventional risk factors [24]. 
However this was not confirmed by Tayfun Shain et al, in a small case-control study of 
patients with permanent AF of different etiologies and assessed through measurement of BNP 
levels and transesophageal echocardiography [25]. These authors concluded that BNP levels 
were higher in mitral stenosis than in other etiologies of AF. No association was found 
between BNP levels and left atrial function in patients with AF due to the probable lack of 
statistical power of the sample (84 patients with AF) [25].   
A recent study, demonstrated a correlation NTproBNP levels and AF duration, 
differentiating recent AF (<48 h –960 pg/ml; CI95% = 236–1328) and progressive AF (>48h –
3695 pg/ml; CI95% =1255-8062). Therefore, NTproBNP levels can be used as negative 
predictive value, with lower values meaning low probability of progressive AF. NTproBNP 
levels were also found to associate with different types of AF: paroxysmal AF with an 
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average value of 1030 pg/ml (CI95% =589-1546 ), persistent with 3658 pg/ml (CI95% = 3112-
5241) and long-standing with 4350 pg/ml (CI95% = 743-8510) (figure 3) [26]. 
However, Deftereos and co-workers, showed different results, which NTproBNP levels 
increases progressively during the first 24 hours and falls rapidly thereafter [27]. Given these 
results, the authors suggested that the NTproBNP levels, could predict the presence of LAA 
thrombus: lower values were associated with LAA thrombus formation, contradicting 
previous results [28]. 
In a cross sectional study of patients with preserved left ventricular (LV) systolic 
function, NTproBNP levels were higher in patients with AF than controls. Higher values were 
found in persistent and permanent AF. This increase may be explained due to structural 
changes, such as atrial enlargement and their loss of contractile function, and ventricular and 
atrial asynchrony [29].    
 
IV. Predictor of recurrence post-atrial fibrillation ablation:  
Fan and colleagues have shown that NTproBNP values are higher in paroxysmal AF 
(when compared with healthy controls) and normalize 3 months after pulmonary vein 
isolation. Furthermore, NTproBNP levels predicted recurrence of AF, with an optimum cutoff 
value of ≥ 423.20 pg / ml [30]. These results have been confirmed by other groups [31, 32]. 
Nilson and co-workers, found that patients with unsuccessful AF ablation displayed 
higher NTproBNP levels after an exercise test on a cycle ergometer. The authors suggested 
that lowers values to predict ablation success (<15 pmol/L) (figure 3) [32]. 
 
V. Predictor of atrial fibrillation after surgery: 
According to Iskesen, elevated NTproBNP before coronary artery bypass grafting, may 
be predictive of the occurrence of postoperative AF [33]. Similar results were found by 
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Gasparovic concerning higher values of preoperative and postoperative NTproBNP [34] and  
Gibson regarding BNP levels [35]. In a previous study, NTproBNP was found to be a 
predictor of AF after coronary bypass surgery on univariate, but not on multivariate analysis 
[36]. This was also shown by Samy and colleagues with NTproBNP cutoff levels of 353 
pg/mL and 307 pg/mL (0 hour and 4 hours, respectively) (figure 3) [37].  
After lung surgery, it was found that patients who develop AF showed higher values of 
this neuropeptide [38]. In postoperative patients with esophageal carcinoma, Hou and co-
workers described a correlation between increased hormone that the presence of AF [39]. 
Similar findings have also been observed in patients with lung cancer [40].   
 
VI. Predictor of recurrence of atrial fibrillation post-cardioversion: 
Freynhofer and collegues established that NTproBNP levels are not useful for predicting 
the stability of cardiac rhythm after cardioversion (CV), because baseline levels and changes 
in this neuropeptide after CV were similar irrespective of the presence of relapse. Although 
NTproBNP levels decreased after CV in all patients and increased solely in the AF recurrence 
group at 6 weeks, interpretation of these results is difficult as these patients were already in 
AF at the time of blood sampling [41].  
Lack of association of NTproBNP with relapse after AF CV was also described Psychari 
and colleagues [42]. 
Wozakowska-Kapłon et al. have shown that both BNP and NTproBNP had no role for 
predicting AF relapse after cardioversion [43].  
Conversely, positive results have also been described: baseline NTproBNP values below 
450 pg/ml predict successful CV, and values greater than 1800 pg/ml, predict AF recurrence. 
Intermediate values provide no information towards this endpoint [44].  
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Likewise, Beck-Da-Silva et al, in patients with persistent AF, BNP levels were associated 
with successful CV. After two weeks of CV, patients who had lower BNP levels, maintained 
a normal sinus rhythm. Although patients with valvular disease or left ventricular dysfunction 
were excluded, the study analyzed only 20 patients [45]. Plasma BNP as a predictor of the 
recurrence of AF, was also described by Lellouche and c-workers (table 1) [46]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Proposal of a diagnostic approach to the patient with atrial fibrillation according to 
BNP/NTptoBNP levels. Cutoff values are presented as a form of illustrating possible cutoff 
values base in presented study results, but an overall flowchart validation is still warranted. 
AF – Atrial Fibrillation; BNP – brain natriuretic peptide; NTproBNP – N-terminal pro brain 
natriuretic peptide; TE – tromboembolic events. 
1
 with anticoagulant therapy 
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2.3. Atherosclerotic Disease: 
In a case-control study, Zhou W. et al analysed 227 pre-dialysis patients with Chronic 
Kidney Disease (CKD) to relate BNP levels with carotid plaques and atherosclerosis. The 
study showed higher BNP levels in CKD patients, which were positively related with the 
intima-media thickness of common carotid artery and left ventricular mass and was 
significantly higher in patients with carotid plaques [12]. 
The hormone may have protective effects on the cardiovascular system, and increased 
BNP concentration may be a response to atherosclerosis in carotid artery stenosis (CAS) 
patients. This may occur through potent peptide induced inhibition of vascular smooth muscle 
cell proliferation and generation of Cyclic Guanosine Monophosphate. Relaxation of the 
atherosclerotic aorta has also been proposed as an adaptive mechanism induced by this 
peptide [47]. 
In a recent nonrandomized clinical trial, Duschek  and co-workers, assessed long term 
mortality of 205 patients with asymptomatic high-grade internal carotid artery stenosis after 
carotid endarterectomy using NTproBNP as a stratification tool. They concluded that the 
increased mortality risk was more pronounced in male patients with higher levels of 
preoperative NTproBNP. When NTproBNP levels were low, the same survival rate was 
observed after surgery independently of age [48].  
It is thought that the predictive role of this neuropeptide reflects its assessment of cardiac 
function, namely hemodynamic stress and pressure load, factors that may render patients 
vulnerable to post-operative events (figure 4) [48].  
An experimental study, evaluated 311 patients undergoing coronary angiography to study 
the relation between BNP levels and the formation of collateral circulation. The authors 
showed that BNP levels were higher in patients with good collaterals, and suggested that this 
may be due to potential stimulation of angiogenesis and arteriogenesis [49]. Furthermore, 
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BNP preconditioning has also been previously shown to decrease myocardial apoptosis 
induced by ischemia-reperfusion injury [12]. However, the main cause of coronary artery 
disease (CAD) is atherosclerosis, which also can increase BNP levels, by mechanisms already 
referred.  Therefore, the results may be misinterpreted.  
It has also been shown that NTproBNP levels may present minor increases in CAD 
patients, without myocardial damage, after exercise [4]. This can be explained by the cardiac 
effort during exercise, with a mismatch in oxygen supply than can cause hemodynamic stress 
and thereby the release of this neuropeptide. 
 
2.4. Aortic valve stenosis (AVS): 
According to Maréchaux and colleagues, plasma BNP level reflects LV size, systolic 
function, disease severity, and NYHA class in patients with AVS. These authors also 
suggested that, in patients with normal LV ejection fraction, plasma BNP levels 
predominantly reflect the consequences of the afterload burden faced by the LV rather than 
the severity of valve stenosis [50].  It is thought that the elevated afterload increases LV 
systolic wall stress, acting as a stimulus for hypertrophy of myocytes, worsening diastolic 
dysfunction and increasing the expression of natriuretic peptides. [51].  
It has been suggested that higher BNP levels, in conjunction with clinical and 
echocardiographic parameters, might be important for the risk stratification of patients. 
Furthermore, preoperative BNP levels can predict the occurrence of perioperative 
complications, and therefore may be considered when selecting the most adequate patients for 
surgery [52]. BNP can also be useful after valve replacement, because it correlate the heart 
function and future postoperative complications, such as, congestive heart failure, renal 
insufficiency, ischemic stroke, and increased rates of rehospitalisation [52]. Similar results 
supporting the role of BNP as a predictor of outcome have been presented by Antonini-
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Canterin et al. (table 1) [53]. The association of elevated BNP levels with a worse outcome, 
reinforces the need of an early detection and referral of severe aortic stenosis for valve 
replacement. 
 
2.5. Cardiomyopathy: 
2.5.1. Hypertrophic cardiomyopathy(HCM): 
Recent studies, have tried to evaluate the prognostic role of BNP/NTproBNP on 
hypertrophic cardiomyopathy. According to Kubo T. et al, BNP levels along with troponin I, 
are useful for predicting cardiovascular events and clinical deterioration [5]. Patients with 
higher BNP levels have more dilated left atria, thicker LV walls, higher prevalence of HCM 
with obstruction and AF. However patients with apical HCM and NYHA functional class I 
can also present with low BNP values.  
In a study by Kitaoka H. et al, BNP was associated with the occurrence of cardiovascular 
events on univariate analysis, but on multivariate logistic regression it was not significantly 
associated with prognosis, since it did not add predictive information to the variables that 
were included in the model: high spetal E/e’ ratio, history of syncope and documentation of 
AF [54].   
Several mechanisms have been proposed for the release of BNP in this disease: the 
presence of a dynamic gradient and associated LV dysfunction, either systolic or diastolic, LV 
hypertrophy and histologic abnormalities that further aggravate diastolic dysfunction and 
abnormal calcium kinetics and subendocardial ischemia. [54] 
 
2.5.2. Tachycardia-mediated cardiomyopathy (TMC): 
In patients with suspected Tachycardia-mediated cardiomyopathy it is necessary to 
accurately confirm if the tachycardia is the primary cause of the patient’s cardiomyopathy, or 
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if the tachycardia is secondary to a cardiomyopathy of different etiology. Besides, there exists 
no specific test or exam to elucidate this problem.  
Nia and colleagues, in a case-control study, including 40 patients with supraventricular 
tachycardia (rest heart rate ≥ 100bpm) and a impaired LV ejection fraction (LV ejection 
fraction < 40%) who underwent successful cardioversion, reported that raised baseline levels 
of NTproBNP followed by a pronounced decrease in the following weeks favoured the 
diagnosis of TMC. A ratio of basal to 1-week after cardioversion NTproBNP of ≥2.3 was 
highly accurate for diagnosing TMC (sensitivity of 84% and specificity of 95%) [55]. 
It is crucial to quantify NTproBNP levels after cardioversion [55], when compared with 
structural heart disease.  In TMC, the cardioversion eliminates the atrial tachyarrhythmias, 
during a time period, allowing recovery of LV systolic dysfunction and decrease of 
NTproBNP levels. Conversely, in patients with structural heart disease, the underlying 
conditions remain constant leading to less pronounced changes in the peptides.  
In the long term, TMC may lead to persistent LV dilatation, diffuse LV fibrosis, and LV 
systolic dysfunction [56] which may alter the previously suggested interpretation of the 
evolution of BNP or NTproBNP levels. Despite this limitation, it seems to be an important 
parameter to differentiate between these two conditions at an early stage (table 1).  
 
2.5.3. Takotsubo cardiomyopathy (TTC): 
Fröhlich and co-workers used the ratios of NTproBNP/myoglobin, NTproBNP/troponin 
T and NTproBNP/creatinekinase-MB to differentiate between TTC (n=39) and ST elevation 
myocardial infarction (STEMI) (n=48) and with non-ST myocardial infarction (NSTEMI) 
(n=34). The best differentiation was attained with the ratio of peak levels of 
NTproBNP/troponin T: a cut-off point of 2889 differentiated TTC from STEMI (sensitivity 
91% and specificity 95%) and a ratio of 5000 distinguished TTC from NSTEMI (sensitivity 
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83% and specificity 95%) [57]. All 3 disease states increase BNP and NTproBNP levels  
mainly due to myocardial stretch and heart failure (figure 4). However, the severity of 
myocardial damage can separate the entities since necrosis markers are elevated specially in 
CAD or other heart diseases causing myocardial necrosis. Contrary to CAD, TTC is 
characterized by reversible damage without necrosis [57].   
Nguyen et al, have also evaluated NTproBNP/BNP levels in 56 patients with TTC that 
were followed during 3 months. TTC was associated with persistent elevation of NTproBNP 
levels in the first 24hours after symptom onset, which correlated with the severity of LV 
systolic dysfunction (assessed by LV ejection fraction and LV wall motion score index). A 
slow but incomplete resolution during the 3 months thereafter was observed [58]. 
 
2.6.Evaluation of surgical patients: 
Plasma NTproBNP levels were proven to be useful for assessing pre-operative NYHA 
and LV ejection fraction and for monitoring haemodynamic status after valve replacement 
surgery. It has been suggested that an evaluation at 1, 7 and 14 days would be more accurate 
than a single measurement, since the peak of biomarker occurs at the 7
th
 day and is then 
followed by a subsequent decrease. [59]. Scachener and colleagues evaluated 819 patients 
undergoing coronary artery bypass grafting and concluded that besides the usually evaluated 
risk factors, NTproBNP was related to higher mortality and more postoperative 
complications. The authors observed that a value of NTproBNP greater than 502 ng / ml 
predicted a higher mid-term mortality and perioperative complications [60].  
Similar results were obtained by Lukasz et al, who verified that NTproBNP levels can be 
used to predict postoperative complications in coronary surgery, namely pulmonary 
outcomes, haemodynamic support and the use of inotropic drugs, length of intensive care unit 
stay and total hospitalization duration [61]. 
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BNP and NTproBNP have also shown a prognostic role or to be predictors of AF after 
non-cardiac surgery. In a meta-analysis of 9 studies, Karthikeyan and colleagues found that 
both pre-operative BNP and NTproBNP were powerful and independent predictors of cardiac 
events within 30 days after non-cardiac surgery [62].  
A recent study has shown that BNP might have a role in the screening of patients that 
might benefit from an echocardiogram before orthopaedic surgery, since elevated BNP levels 
predicted structural cardiac disease detectable in that examination [63]. Two investigations in 
the orthopaedic setting [64, 65] confirm the findings of the previously mentioned meta-
analysis. 
 
2.7.Kawasaki disease:  
BNP plasma levels significantly increase, despite well-preserved global left ventricular 
function, in Kawasaki disease, namely in the acute phase [66]. The suggested trigger for the 
release of the neuropeptide in this setting is thought to be coronary artery inflammation. 
 
2.8.Central Sleep Apnea (CSA): 
CSA is associated with obstructive sleep apnea syndromes or is caused by an underlying 
medical condition, namely heart failure (HF). Moreover, the risk of CSA is higher according 
to the severity of HF. Accordingly, higher levels of BNP are associated with higher risk for 
CSA in men (table 1) [67]. This association may be triggered by pulmonary congestion, 
through vagal receptors that lead to intermittent hyperventilation and hypocapnia (figure 4) 
[68].  
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2.9. Sepsis:  
Both BNP and NTproBNP levels increase alongside with sepsis severity, which is 
correlated with early systolic dysfunction [4, 69]. Using this marker in early sepsis, it is 
possible to identify occult systolic dysfunction and provide a chance for timely treatment. 
Moreover, BNP levels are positively correlated to the risk of mortality, which renders this 
biomarker a promising prognostic tool for these patients [69]. These neuropeptides may, 
therefore, used to target patients with higher risk of complications, and who may benefit from 
a more aggressive treatment (table 1).  
 
4.10.Chronic kidney disease (CKD): 
As Duali S. et al suggested, in children with CKD, BNP is a powerful tool to predict 
adverse events related to the progression of disease, namely cardiovascular complications and 
mortality [70]. However, it is necessary to adjust the threshold in these patients, since renal 
dysfunction itself can influence these values. NTproBNP and BNP levels were inversely 
correlated with glomerular filtration rate, and consequently CKD increased the concentrations 
of both peptides, influencing the cut-off points. Nevertheless, NTproBNP is slightly more 
influenced than BNP, probably due to the different pathways for clearance: BNP is cleaved by 
neutral endopeptidase before undergoing renal elimination. NTproBNP does not share this 
metabolic step and depends more of of renal elimination [3,4].  
 
4.11. Pleural effusions:  
Measuring plasma and pleural fluid BNP can help in accurately diagnosing the etiology 
of pleural effusions. It was reported that a cut-off point of 132pg/ml for plasma BNP 
(sensitivity 97.1% and specificity 97.4%) and 127pg/ml for pleural fluid BNP (sensitivity 
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97.1% and specificity 87.8%) was highly suggestive of pleural effusion due to heart failure 
[71].  
 
4.12. Alcoholism: 
Hofer and co-workers evaluated 83 alcohol-dependent patients, with an average 
consumption of 170 g / day, without cardiac disease or liver disease. Elevated NTproBNP 
levels on admission were observed in 52% despite a normal LV ejection fraction. This could 
be explained by either the presence of subclinical cardiac damage not translated in changes of 
LV ejection fraction (figure 4), adrenergic activation, alterations in volume state due to 
alcohol intake or interaction in hepatic metabolism of the biomarker [72]. After treatment of 
alcohol dependence, NTproBNP values decreased despite unchanged LV ejection fraction, 
establishing a cause-effect relationship between alcohol intake and NTproBNP levels (table 1) 
[72]. 
 
4.13. Chronic Obstructive Pulmonary Disease (COPD): 
A prospective study, by Sanchez, evaluated 99 patients with an acute exarcebation of 
chronic obstructive pulmonary disease (COPD) and no history of cardiac disease. They 
observed that during acute exacerbation of COPD, elevated NTproBNP levels were frequently 
found and seemed to identify patients at risk of a worse clinical evolution [73].  
Gale and colleagues, reported that the NTproBNP was a predictor of survival of these 
patients. However, NTproBNP values were associated with the length of stay in hospital [74]. 
Medina et al evaluated 192 patients admitted due to acute exacerbations of COPD and 
measured NTproBNP at 72 hours after admission and 12 months later. NTproBNP levels 
correlated with the number of hospitalization days and adverse outcomes at 12-months. 
Values over 587.9pg/ml were associated with a 4-fold higher one year mortality (table 1) [75].  
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Figure 4 - Discussion of the relationship between different diseases and NTproBNP/BNP. AF 
– atrial fibrillation; AS – artery stenosis; BNP – brain natriuretic peptide; COPD – chronic 
obstructive pulmonary disease; CSA – central sleep apnea; HCM – hypertrophic 
cardiomyopathy; NTproBNP – N-terminal pro brain natriuretic peptide; TMC – tachycardia-
mediated cardiomyopathy; TTC - takotsubo cardiomyopathy. 
 
 
 
 
 
 
 
 
 
 
Table 1 – Key ideas about role of BNP/NTproBNP in diverse diseases.
Disease BNP NTproBNP Role Ref.
Ischemic Stroke ↑↑ ↑
- BNP: Elevated in Stroke and TIA;
- Predictor of CE stroke;
- Higher in patients without angiographic vasospasm;
- NTproBNP: Alongside with the NIHHS scale allows risk stratification and 
prognostication of patients;
-  Predictor of CE stroke;
 1,6, 8-14
Atrial 
Fibrillation ↑ ↑↑
- BNP: Predictor of LAA dysfunction and LA thrombus;
- Predictor of AF incidence after stroke;
- Predictor of thromboembolic events (under anticoagulant therapy);
- Predictor of AF recurrence after cardiac surgery and cardioversion;           
- NTproBNP: Predictor of  AF incidence or AF type;
- Predictor of AF duration;
- Predictor of stroke and mortality rate;
- Predictor of AF recurrence after ablation, cardiac and non-cardiac surgerya and 
cardioversion;
6, 14-45
Atherosclerotic 
Disease ↑            ↑
Carotid Artery Stenosis
-  BNP is correlated with atherosclerosis; 
-  Higher NTproBNP  levels associated with long term mortality;
-  Low levels identify patients with low surgical risk, even among elderly.
Coronary Artery Disease
- Patients with good collaterals have higher BNP level;
-  NTproBNP may increase after exercise.
4, 12, 46-48
Aortic valve 
stenosis ↑
- Plasma BNP level reflects LV size, systolic function, disease severity, and 
NYHA class;
- Higher levels associate more with LV afterload than with stenosis severity;
- Risk stratification after valve replacement.
49-52
Hypertrophic 
cardiomyopathy ↑
- BNP alongside with other markers (troponin I) can predict progression of 
disease, but not when isolated;
- Predict cardiovascular events.
5, 53
Tachycardia-
mediated 
cardiomyopathy
↑
- Early diagnosis of TMC before and after cardioversion;
- Differentiate from structural heart disease. 54, 55
Takotsubo 
cardiomyopathy ↑ ↑
- Aid in distinguishing TTC from  acute coronary syndrome (associated with 
necrosis markers);
- TTC is correlated with the severity of LV systolic dysfunction. 
56, 57
Evaluation of 
surgical patients ↑ ↑
- BNP: Risk of perioperative event and cardiac mortality, in patients undergoing 
major non-cardiac surgery;
- NTproBNP: Useful for assessing cardiac function and post operative dynamics 
in valve replacement and  coronary surgery;
- Predict postoperative complications (e.g. pulmonary outcomes, need of 
haemodynamic support);
58-65
Kawasaki 
disease       ↑
-In the acute phase, BNP levels increase, despite well-preserved global LV 
function;
66
CSA ↑ -Risk of CSA is related to higher concentrations of BNP levels; 67, 68
Sepsis ↑ ↑ - BNP/NTproBNP levels are associated with sepsis severity;- Higher BNP levels are correlated with higher levels of mortality;
4, 69
CKD ↑ ↑ -BNP is useful to predict adverse events and mortality in patients with CKDb; 3, 4, 12, 70
Pleural 
effusions ↑
-Plasma and pleural fluid BNP can aid in the diagnosis of pleural effusions due to 
heart failure;
71
Alcoholism ↑
-Alcohol consumption leads to an increase of NTproBNP, independent of 
ejection fraction;
-After treatment of alcohol dependence, NTproBNP values decreased despite 
ejection fraction remain constants;
72
COPD ↑
-NTproBNP is a prognostic factor in acute exacerbation;
- Associated with hospital stay; 
- Lower NTproBNP levels are correlated with best prognostic in a year.
73-75
Legend: AF – atrial fibrillation; BNP – brain natriuretic peptide; CAD – coronary artery disease; CE – cardioembolic; CKD – chronic kidney 
disease; COPD – chronic obstructive pulmonary disease; CSA – central sleep apnea; ; ICU – intensive care unit; NIHSS - National Institutes of 
Health Stroke Scale; NTproBNP – N-terminal pro brain natriuretic peptide; LAA - left atrial appendage; LV – left ventricle; TIA – transient  
ischemic attack; TMC – tachycardia-mediated cardiomyopathy; TTC – takotsubo cardiomyopathy.
a lung and esophageal surgery.
b Both peptides are affected to renal clearance, especially NTproBNP, and their cut-off points must be adjusted to other pathologies, when  
simultaneous with CKD.
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Conclusion 
The purpose of this study was to assess the usefulness of BNP/NTproBNP levels among 
different diseases beyond heart failure. Both peptides levels have been correlated with several 
diseases, which may affected their release to the bloodstream and eliminations. Therefore, it is 
crucial to be aware of these interferences, in order to achieve and adjust optimal cut-off points 
to each disease.  
In disease states other than heart failure, BNP and NTproBNP are reliable biomarkers to 
detect early stages and for the evaluation of severity as prognosis.  
Further studies are needed to better define the clinical applications of BNP and 
NTproBNP, to evaluate the relevance of serial assessment for optimal clinical decision. Due 
to the variety of existing laboratory tests and reference values, external validation of results 
may be an issue to deal before implementing decision trees based on peptide levels. 
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